51 Radiation exposure during percutaneous coronary intervention: insights from the REVIVED-BCIS2 trial

Abstract

Introduction Percutaneous coronary intervention (PCI) is used to treat increasingly complex coronary disease but requires exposure to ionising radiation. The additional risk of incident cancer from these exposures has generally been considered clinically insignificant. Recent data from the REVIVED-BCIS2, EXCEL and ISCHEMIA trials have, however, signalled higher Abstract 51 Figure 1 a logarithmic (base 2) chart highlighting the DAP received by patients at the lead centre for REVIVED-BCIS2 from their PCI procedure alone, excluding radiation dosage from angiography.